Connect with us

Hi, what are you looking for?

Trade News

Cardiex September 2024 Quarter Update

Cardiex Limited (ASX:CDX) (the “Company”) is pleased to report its activities during the September quarter 2024.

Highlights:

Manufacturing of the initial 8,000 CONNEQT Pulse units commenced with the expected arrival of units in the USA late-November/early December. Pulse waitlist now exceeds 20,000 with activities now focused on sales conversion. Completed clinical validation study of wearable technology, with an FDA pre-submission meeting scheduled for November to advance the clearance process. Completion of usability study for submission for additional OTC clearance for the Pulse. Strong clinical sales pipeline with momentum towards new Q2 contracts. Grand prize winner of the U.S. National Institute of Health’s RADx® Maternal Health Challenge securing US$525,000 in prize funding. New R&D Term Loan Facility with Mitchell Asset Management to provide additional flexibility with R&D initiatives and working capital requirements.

Click here for the September Quarterly Appendix 4C

Click here for the full ASX Release

This post appeared first on investingnews.com

You May Also Like

Stock News

​​​Global cyber outage disrupts multiple industries ​A widespread cyber outage has struck various sectors globally, causing significant disruptions to airlines, media companies, banks, and...

Stock News

Previous trading outcomes In this week’s episode of “Trading the trend,” Axel Rudolph recaps recent trades, starting with the lucrative long position in spot...

Stock News

​​​Gold sees bullish momentum fade ​Spot gold price soared this week to a new record, but have eased off over the previous two sessions,...

Stock News

​​​Strong growth underpins share price rally Rolls-Royce demonstrated impressive growth in 2023, with underlying operating profit surging 144% to £1.59 billion and free cash...